Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
We have worked with over 2000 companies, investors and research institutions.
All clients, by client group
- Alliance Foundation Trials, LLC
- Bluefield Project to Cure FTD
- Children's Urological Foundation
- Commonwealth Cancer Consortium (Break Through Cancer)
- Cure GM1 Foundation
- Foundation for Angelman Syndrome Therapeutics (FAST)
- Global Alliance for TB Drug Development
- The N=1 Collaborative, Inc.
- Tufts University
- ActNano, Inc.
- Ambulomics, Inc.
- Biobot Analytics, Inc.
- Breathe BioMedical Inc. (Canada)
- CAMP4 Therapeutics, Inc.
- Day Zero Diagnostics, Inc.
- Dialco Medical Inc.
- eGenesis Inc.
- GelMEDIX, Inc.
- HighRes Biosolutions, Inc.
- Instylla, Inc.
- JC Medical, Inc.
- Moximed, Inc.
- Palette Life Sciences AB
- PolarSeal Tapes & Conversions Ltd.
- Polypeptide Therapeutic Solutions US - Curapath
- Reveal Pharmaceuticals, Inc.
- SAGA Dx, Inc.
- Salmoss SpA
- Savran Technologies Inc.
- Sirtex Technology Pty Ltd
- Spectral Medical Inc.
- Tides Medical, LLC
- Vizgen, Inc.
- 65 Therapeutics, Inc.
- Abata Therapeutics, Inc.
- Abcentra LLC
- Accent Therapeutics, Inc.
- Actithera, Inc.
- Adrenas Therapeutics, Inc.
- Aerium Therapeutics, Inc.
- Affini-T Therapeutics, Inc.
- Affinia Therapeutics, Inc.
- Akebia Therapeutics, Inc.
- Aktis Oncology, Inc.
- Aldeyra Therapeutics, Inc.
- Aliada Therapeutics, Inc.
- Allorion Therapeutics Inc.
- Alltrna, Inc.
- Allyx Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Alpheus Medical, Inc.
- Amide Technologies
- Ananda Scientific, Inc.
- Angiex, Inc.
- Anokion US, Inc.
- Anthos Therapeutics, Inc.
- Antidote Therapeutics, Inc.
- Apic Bio, Inc.
- Apollo Therapeutics Limited
- Arbor Biotechnologies, Inc.
- Arcadia Science LLC
- ARMGO Pharma, Inc.
- Artax Biopharma, Inc.
- ARTBIO Inc.
- AS2 Bio Inc.
- AsclepiX Therapeutics, Inc.
- Aspa Therapeutics, Inc.
- Astria Therapeutics, Inc.
- Atavistik Bio
- Atomwise Inc.
- aTyr Pharma, Inc.
- Aura Biosciences, Inc.
- AvenCell Therapeutics, Inc.
- Avenzo Therapeutics, Inc.
- Axial Therapeutics, Inc.
- Azkarra Therapeutics, Inc.
- Betagenon AB
- Bicara Therapeutics Inc.
- Bill & Melinda Gates Foundation and the Bill & Melinda Gates Medical Research Institute
- BIORCHESTRA Co., Ltd.
- Blue Oak Pharmaceuticals, Inc.
- BridgeBio Oncology Therapeutics
- Cambrian BioPharma, Inc.
- Carbon Biosciences, Inc.
- Cardurion Pharmaceuticals, Inc.
- CG Pharmaceuticals, Inc.
- Chordia Therapeutics, Inc.
- Chrysalis Genetics Inc.
- Claris Biotherapeutics, Inc.
- Cloverleaf Bio, Inc.
- Cora Biosciences, Inc.
- Corner Therapeutics, Inc.
- Cullinan Therapeutics, Inc.
- Cyteir Therapeutics, Inc.
- Deciphera Pharmaceuticals, LLC
- Delphia Therapeutics, Inc.
- DEM BioPharma, Inc.
- DG Medicines, Inc.
- Dianthus Therapeutics OpCo, Inc.
- Dicerna Pharmaceuticals, Inc.
- Diceros Therapeutics, Inc.
- Disc Medicine, Inc.
- Dispatch Biotherapeutics, Inc.
- Domain Therapeutics USA, Inc.
- Eicosis LLC
- Elicio Therapeutics, Inc.
- Emerald Lake Safety LLC
- Epalex Corporation
- Eumentis Therapeutics, Inc.
- EvolveImmune Therapeutics, Inc.
- Expansion Therapeutics, Inc.
- Forma Therapeutics, Inc.
- Garuda Therapeutics, Inc.
- General Oncology, Inc.
- Genus Lifesciences Inc.
- Ghrelco, Inc.
- GV.M1 Inc.
- GV20 Therapeutics LLC
- hC Bioscience, Inc.
- Helix Nanotechnologies, Inc.
- Hemab ApS
- Hillstar Bio, Inc.
- HUTCHMED Limited
- Hyku Biosciences, Inc.
- IDBiologics, Inc.
- IDEAYA Biosciences, Inc.
- Ikena Oncology, Inc.
- Immunocodex, Inc.
- ImmunoGen, Inc.
- Jumble Therapeutics, Inc.
- KalVista Pharmaceuticals, Inc.
- Kanyos Bio, Inc.
- Kelonia Therapeutics, Inc.
- Korro Bio, Inc
- KSQ Therapeutics, Inc.
- Lightship Scientific Consulting, LLC
- Linden Lake Labs
- Lumen Bioscience, Inc.
- Lyra Therapeutics, Inc.
- Macrotope, Inc.
- Magnet Biomedicine, Inc.
- Mahzi Therapeutics
- Merlin Therapeutics, Inc.
- Mnemo Therapeutics SAS
- Modal Therapeutics, Inc.
- Myeloid Therapeutics, Inc.
- Neomorph, Inc.
- Neurogastrx, Inc.
- NextPoint Therapeutics, Inc.
- NextRNA Therapeutics, Inc.
- Nilo Therapeutics, Inc.
- Normunity AccelCo, Inc.
- Normunity, Inc.
- NorthSea Therapeutics, B.V.
- Novo Nordisk A/S
- Nucyrna Therapeutics, Inc.
- Nurix Therapeutics, Inc.
- Obsidian Therapeutics, Inc.
- Okava Pharmaceuticals, Inc.
- Olaris Inc.
- Oligomerix, Inc.
- OneCyte Biotechnologies, Inc.
- ONK Therapeutics Limited
- Onsero Therapeutics Inc
- Orna Therapeutics, Inc.
- Oviva Therapeutics, Inc.
- PanOptica, Inc.
- PanTher Therapeutics, Inc.
- Paragon Therapeutics, Inc.
- Pathalys Pharma, Inc.
- PepGen Inc.
- perForm biologics, inc.
- Permeasis Therapeutics, Inc.
- PharmaEssentia USA Corporation
- Pheon Therapeutics Ltd.
- Phylaxis Bioscience, LLC
- PIC Therapeutics, Inc.
- Pliant Therapeutics, Inc.
- Potens Animal Health
- Praeventix, Inc.
- Prokarium Ltd
- ProThera Biologics, Inc.
- Puma Biotechnology, Inc.
- Q1, Inc.
- Q2, Inc.
- QurAlis Corporation
- Rapalogix Health, Inc.
- Red Arrow Therapeutics, Inc.
- Rekindle Therapeutics Inc.
- Relay Therapeutics, Inc.
- RemeGen Biosciences, Inc.
- Repertoire Immune Medicines
- Revalia Bio, Inc.
- Revelio Therapeutics Inc.
- Rgenta Therapeutics, Inc.
- Rhoshan Pharmaceuticals, Inc.
- Ribo Therapeutics Inc.
- Right Brain Bio, Inc.
- Rila Therapeutics, Inc.
- RocketVax AG
- Rome Therapeutics, Inc.
- Sage Therapeutics, Inc.
- Sail Biomedicines, Inc.
- SalioGen Therapeutics, Inc.
- Scorpion Therapeutics, Inc.
- Seismic Therapeutic, Inc.
- Senda Biosciences, Inc.
- Severin Therapeutics, Inc.
- Sieben Therapeutics, Inc.
- SLAP Pharmaceuticals, LLC
- SNIPR BIOME ApS
- SonALAsense, Inc.
- Sonoma Biotherapeutics, Inc.
- SOTIO Biotech Inc.
- Souffle Therapeutics
- Stoke Therapeutics, Inc.
- STORM Therapeutics Ltd.
- Strand Therapeutics, Inc.
- Stylus Medicine, Inc.
- Sudo Biosciences Inc.
- Sudo Biosciences Limited
- Summation Bio, Inc.
- SURGE Therapeutics, Inc.
- Syndax Pharmaceuticals, Inc.
- Synedgen, Inc.
- Synthego Corporation
- Tasca Therapeutics Corp.
- Tectonic Therapeutic, Inc.
- TFC Therapeutics, Inc.
- Theaprin Pharmaceuticals, Inc.
- Theragnostics Ltd.
- Thymmune Therapeutics, Inc.
- TMS Co., Ltd.
- Torqur AG
- TransformaTX Biotherapeutics LLC
- Treadwell Therapeutics, Inc.
- TScan Therapeutics, Inc.
- Upstream Bio, Inc.
- Vernal Biosciences, Inc.
- Verra Therapeutics, LLC
- Versatope Therapeutics, Inc.
- Verseau Therapeutics, Inc.
- Verve Therapeutics, Inc.
- Vicore Pharma AB
- Vigil Neuroscience, Inc.
- Viridian Therapeutics, Inc.
- Viridian, LLC
- viTToria bioTherapeutics, Inc.
- Volastra Therapeutics, Inc.
- Volstra Therapeutics
- Voronoi, Inc.
- Voyager Therapeutics, Inc.
- YZ Advanced CGT Consulting, LLC
- Zenas BioPharma
- Zenon Biotech, Inc.
- Curated Planet, LLC
- Gleason Technology, Inc.
- GlobalSign, Inc.
- iCapture
- IQ Proteomics, LLC
- Liteboxer Technologies, Inc.
- Micropsi Industries, GmbH
- Muzooka, Inc.
- Optera Life Sciences, LLC
- Parking Edge LLC
- Sibyl Analytics, LLC
- Transformate, LLC
- YBRP, Inc.
- 4D Molecular Therapeutics, Inc.
- 5AM Venture Management LLC
- AllerFund Ventures, LLC
- ARCH Ventures
- Columbus Venture Partners, SGEIC, SAU
- Cosmos Scope Management S.A.
- CoVenture
- Cure Ventures Management, L.P.
- Delos Advisors Limited
- Flagship Pioneering
- GG1978 SICAF SIF
- GISEV EH LLC
- GV (Google Ventures)
- ShangPharma Innovation, Inc.
- Vesper Biotech Fund I, LP
- Westlake BioPartners, LLC
Recent transactions
Claris Biotherapeutics, Inc.
Series A-3 Preferred Stock FinancingClaris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors
Press Release
GV (Google Ventures) + ARCH Ventures
Chroma Medicine Series B FinancingRepresentation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing
Press Release
NextPoint Therapeutics, Inc.
Series B Financing - $80 millionNextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute
Website
Paragon Therapeutics, Inc. + Apogee Therapeutics, Inc.
Antibody Discovery and Option AgreementOption for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions
Press Release
6 Dimensions Capital
VC InvestmentsEquity investments in multiple portfolio companies, including Hibercell
Website
Puma Biotechnology, Inc.
Clinical TrialCRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification
See Study
Epalex Corporation
Series A-3 FinancingSeries A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs
Website
Vertex Pharmaceuticals Incorporated
Acquisition of Private CompanyCo-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine
Press Release
Versant Ventures Management, LLC
Antibody Discovery and Collaboration AgreementMulti-year collaboration with AbCellera to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechnology companies
Press Release
Vizgen, Inc.
Series C FinancingVizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors
Press Release